- $99.56m
- $40.32m
- $237.26m
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts
Factbox: US Health Secretary Kennedy's vaccine actions and policy positions
Brief: Vaxart Announces Withdrawal Of Reverse Stock Split Proposal
Brief: Concerned Vaxart Stockholders Reiterate Intent To Vote Against Reverse Stock Split At Sept 19 Special Meeting
Brief: Vaxart Appoints W. Mark Watson As Lead Independent Director
Factbox: US Health Secretary Kennedy's vaccine actions and policy positions
Brief: Vaxart Announces Retirement Of Chairman Michael J. Finney, Ph.D. From The Board Of Directors
Brief: Concerned Vaxart Stockholders Urge Fellow Stockholders To Vote “Against” Reverse Stock Split And Demand Board Accountability
US orders Vaxart to stop COVID-19 trial amid mRNA wind down
Brief: Vaxart Submits Proxy Statement For Reverse Stock Split
U.S. STOCKS ON THE MOVE-Caterpillar, Starbucks, Lockheed Martin
U.S. STOCKS ON THE MOVE-Vaxart, DoubleVerify, Cracker Barrel
U.S. STOCKS ON THE MOVE-MP Materials, Ouster, Tesla
Vaxart soars on early-stage data of its new norovirus vaccine
Brief: Vaxart Reports Positive Clinical Data Demonstrating Second-Generation Vaccine Technology Produces Stronger Antibody Responses Than First-Generation
Brief: Vaxart Announces Adjournment Of Annual Meeting Of Stockholders